Open questions between immune checkpoint inhibitors and tuberculosis incidence

被引：0
|
作者：
Wen, Ying [1 ]
Kang, Jing [2 ]
机构：
[1] China Med Univ, Affiliated Hosp 1, Dept Infect Dis, 155 Nanjing North St, Shenyang 110001, Peoples R China
[2] China Med Univ, Hosp China Med Univ 1, Natl Clin Res Ctr Lab Med, State Key Lab Diag & Treatment Infect Dis,NHC Key, Shenyang, Peoples R China
来源：
JOURNAL OF THORACIC DISEASE | 2024年 / 16卷 / 08期
关键词：
D O I：
10.21037/jtd-24-890
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：5484 / 5486
页数：3
相关论文
共 50 条
  • [1] Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
    Fujita, Kohei
    Yamamoto, Yuki
    Kanai, Osamu
    Okamura, Misato
    Hashimoto, Masayuki
    Nakatani, Koichi
    Sawai, Satoru
    Mio, Tadashi
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (05):
  • [2] Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
    Fujita, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [3] MYOCARDITIS AND RHABDOMYOLYSIS INCIDENCE WITH IMMUNE CHECKPOINT INHIBITORS
    Bloomer, Tyler
    Alexander, Matthew
    Lenihan, Daniel
    Slosky, David
    Becker, Jason
    Sosman, Jeffrey
    Johnson, Douglas
    Moslehi, Javid
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 943 - 943
  • [4] Questions asked in the everyday practice: immune checkpoint inhibitors
    Haanen, John B. A. G.
    ESMO OPEN, 2018, 3 (04)
  • [5] Immune Checkpoint Inhibitors in Cancer Treatment and Incidence of Pancreatitis
    Nwankwo, Oluchukwu Chimuanya
    Lara-Salazar, Francisco Martin
    Lara-Salazar, Santiago
    Abdulrahim, Abdulrashid Onimisi
    Chijioke, Ijeoma
    Singh, Jyoti
    Koradia, Ikhlaq
    Gomez, Nicole M.
    Prakash, Rohit
    Gopagoni, Ragini
    Joshi, Megha
    Rai, Manju
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [6] Pulmonary tuberculosis associated with immune checkpoint inhibitors: a pharmacovigilance study
    Zhu, Jianhong
    He, Zhichao
    Liang, Dan
    Yu, Xiaoxia
    Qiu, Kaifeng
    Wu, Junyan
    THORAX, 2022, 77 (07) : 721 - 723
  • [7] Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors
    Im, Yunjoo
    Lee, Jeeyun
    Kim, Seok Jin
    Koh, Won-Jung
    Jhun, Byung Woo
    Lee, Se-Hoon
    RESPIRATORY MEDICINE, 2020, 161
  • [8] Immune checkpoint inhibitors and tuberculosis: an old disease in a new context
    Langan, Ewan A.
    Graetz, Victoria
    Allerheiligen, Judith
    Zillikens, Detlef
    Rupp, Jan
    Terheyden, Patrick
    LANCET ONCOLOGY, 2020, 21 (01): : E55 - E65
  • [9] Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors
    Laenens, D.
    Yu, Y.
    Santens, B.
    Jacobs, J.
    Beuselinck, B.
    Bechter, O.
    Wauters, E.
    Staessen, J.
    Janssens, S.
    Van Aelst, L.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2565 - 2565
  • [10] Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors
    Laenens, Dorien
    Yu, Yuling
    Santens, Beatrice
    Jacobs, Johanna
    Beuselinck, Benoit
    Bechter, Oliver
    Wauters, Els
    Staessen, Jan
    Janssens, Stefan
    Van Aelst, Lucas
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (29) : 3430 - +
12345